Investing.com - Mesoblast reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Mesoblast announced earnings per share of $-0.185 on revenue of $2.4M. Analysts polled by Investing.com anticipated EPS of $-0.1833 on revenue of $2.49M.
Mesoblast shares are up 11.65% from the beginning of the year and are trading at $6.010 , down-from-52-week-high.They are under-performing the Nasdaq which is up 19.86% from the start of the year.
Mesoblast follows other major Healthcare sector earnings this month
Mesoblast's report follows an earnings beat by J&J on Tuesday, October 19, 2021, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.
Thermo Fisher Scientific had beat expectations on Wednesday with third quarter EPS of $5.76 on revenue of $9.33B, compared to forecast for EPS of $4.68 on revenue of $8.33B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar